

JUN 08 2005

ATTORNEY DOCKET NO. 37629-0076US

**AMENDMENTS****In the Specification**

On the first page, after the title and before Background Of the Invention, please delete the paragraph presented in the Amendment filed November 15, 2004 and replace it with the following paragraph:

This application is a Divisional of U.S. Serial No. 09/495,880 filed February 1, 2001, now Patent No. 6,667,150, which is a continuation of International Application PCT/EP98/04836, filed August 3, 1998. Application Serial No. 09/495,880 is incorporated herein in its entirety by reference hereto.

On page 20, second paragraph, please replace the material mistakenly added in the amendment filed November 15, 2004, with the material mistakenly deleted:

To prove that only the correct phage vector is present in SIP polyphage transductants, DNA of positive (fpep3\_1B-IR3seq3/ pIG10.3-IMPp75) and negative (fjun\_1B-IR3/ pIG10.3-IMPp75) control co-transformants, as well as DNA from the SIP polyphage transductants derived from SIP phages produced by the mix of positive and negative control bacteria was analyzed by PCR (Fig. 8). Primers FR614 (5'-GCTCTAGATAACGAGGGC-3' (SEQ ID NO 49)) and FR627 (5'-CGCAAGCTTAAGACTCCTTATTACGC-3' (SEQ ID NO 50)) amplify the phage region from the start of ompA to the end of gIII. PCR products derived from fpep3\_1B-IR3seq3 and fjun\_1B-IR3 can be discriminated by size. Gel analysis of the above samples verified that only the expected fpep3\_1B-IR3seq3 phage was present in SIP polyphage transductants (6 analyzed).